Browsing Tag
Cloudbreak Pharma
1 post
Cloudbreak Pharma’s CBT‑004 Phase 2 success raises hopes for first approved vascularized pinguecula therapy
Cloudbreak Pharma’s CBT‑004 eye drop hit its Phase 2 targets—find out why it could become the first approved vascularized pinguecula therapy by 2028.